Theralase Technologies Inc. (TLT.V)
- Previous Close
0.1650 - Open
0.1700 - Bid 0.1600 x --
- Ask 0.1700 x --
- Day's Range
0.1650 - 0.1700 - 52 Week Range
0.1600 - 0.3100 - Volume
82,500 - Avg. Volume
130,072 - Market Cap (intraday)
38.796M - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 28, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. The company was incorporated in 1989 and is based in Toronto, Canada.
www.theralase.comRecent News: TLT.V
Performance Overview: TLT.V
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLT.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLT.V
Valuation Measures
Market Cap
38.80M
Enterprise Value
39.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
33.91
Price/Book (mrq)
20.36
Enterprise Value/Revenue
36.57
Enterprise Value/EBITDA
-9.20
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-77.21%
Return on Equity (ttm)
-182.91%
Revenue (ttm)
1.07M
Net Income Avi to Common (ttm)
-4.57M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
43.91k
Total Debt/Equity (mrq)
20.30%
Levered Free Cash Flow (ttm)
-2.09M
Research Analysis: TLT.V
Company Insights: TLT.V
TLT.V does not have Company Insights